MONITOR THIS FUND
Become an Insider Gold member to monitor your funds.

-212.32  /  -0.57%

37307.64

NAV on 2019/05/20
NAV on 2019/05/17 37519.96
52 week high on 2018/08/29 40279.83
52 week low on 2019/01/02 34967.36
Total Expense Ratio on 2019/03/31 0.92
Total Expense Ratio (performance fee) on 2019/03/31 -0.07
NAV Incl Dividends
1 month change -5.48% -5.48%
3 month change 0.78% 0.78%
6 month change 3.56% 4.72%
1 year change -5.56% -3.41%
5 year change 0% 0%
10 year change 0% 0%
Price data is updated once a day.
  • Sectoral allocations
Basic Materials 684.06 22.03%
Consumer Goods 298.38 9.61%
Consumer Services 231.81 7.46%
Financials 920.49 29.64%
General Equity 42.88 1.38%
Health Care 177.74 5.72%
Industrials 333.60 10.74%
Liquid Assets 118.85 3.83%
Technology 279.86 9.01%
Telecommunications 17.75 0.57%
  • Top five holdings
 NASPERS-N 279.86 9.01%
 SASOL 253.69 8.17%
 BATS 215.43 6.94%
 STANBANK 188.88 6.08%
 REMGRO 151.97 4.89%
  • Performance against peers
  • Fund data  
Management company:
Allan Gray Unit Trust Management (RF) Pty Limited
Formation date:
2015/03/19
ISIN code:
ZAE000202404
Short name:
U-AGSAEQU
Risk:
Unknown
Sector:
South African--Equity--General
Benchmark:
FTSE/JSE All Share Index
Contact details

Email
info@allangray.co.za

Website
http://www.allangray.co.za

Telephone
021-415-2301

  • Fund management  
Duncan Artus
Duncan joined Allan Gray in 2001 as an equity analyst after completing his Honours in Business Science and post graduate diploma in Accounting at the University of Cape Town. He is a CFA charter holder and was appointed a trainee portfolio manager in January 2003.
As of 1 January 2005, Duncan was promoted to the position of portfolio manager and will be managing a portion of the balanced and equity portfolios of the segregated and life clients.
Andrew Lapping
Simon Raubenheimer
Ruan Stander
Jacques Plaut


  • Fund manager's comment

Allan Gray SA Equity comment - Dec 18

2019/03/25 00:00:00
''In the short run, the market is a voting machine but in the long run it is a weighing machine.'' - Benjamin Graham
2018 was a disappointing year for South African equity investors, with the FTSE/ JSE All Share Index returning -9%. The good news is that based on our research the companies we hold in the Fund should generate healthy returns going forward under most scenarios. British American Tobacco (BAT) is a share that detracted significantly from returns during the year and therefore I thought it a good one to discuss.
BAT, in my opinion, is a good example of a company where the market’s ‘voting machine’ (valuing companies like a popularity contest) and ‘weighing machine’ (valuing companies on their actual worth) are in conflict. The voting machine part of the stock market is arguably trying to anticipate investors’ reactions to the next regulatory announcement from the US Food and Drug Administration (which wants to ban menthol cigarettes). What the voting machine ignores is the company’s long track record of compounding earnings for investors through various regulatory changes, as well as evidence that BAT’s investments into next-generation products are starting to bear fruit. BAT has grown its earnings by 12% p.a. since 2001, while paying out 63% of earnings in dividends and investing heavily to develop and distribute next-generation products that significantly reduce the health impact of smoking. A recent update from the company shows it is gaining traction in rolling out these products: BAT’s vaping volumes in the USA, the largest vaping market globally, grew about 40% in the second half of 2018. Three scenarios could play out for BAT. Assuming BAT’s portfolio of nextgeneration products helps it to sustain its 17-year track record, an investor today would earn 20% p.a. (growth of 12% p.a. + dividend yield of 7.8%). One could argue that sentiment towards tobacco shares will remain subdued, but there is a scenario where the weighing machine takes over at some stage over the next four years. This would cause the share to price in its track record, resulting in a higher return (assuming a re-rating to a 5% dividend yield results in 32% p.a.). Under a bad scenario (the FDA succeeds in banning menthol and BAT doesn’t retain any menthol-smoking customers) regulatory intervention dampens growth. Under such a scenario the company may only grow earnings by inflation over the next four years. At the current price this still results in a good outcome with a total return of 14% p.a. (6% growth + 7.8% dividend yield). The weight one should place on the 14%, 20% or 32% p.a. scenarios is ultimately subjective, but these scenarios illustrate the impact of the ‘voting machine’ on BAT’s current share price and the opportunity that this offers to long-term investors.
BAT, or any of the shares we own, could experience unforeseen events outside the scenarios considered. However, at a portfolio level I think now is a good time to be an Equity Fund investor.
During the quarter we bought Richemont and Glencore and we sold Sasol and Old Mutual.
Commentary contributed by Ruan Stander
  • Fund focus and objective  
The Fund invests in shares listed on the Johannesburg Stock Exchange (JSE). The Fund is typically fully invested in shares. Returns are likely to be volatile, especially over short- and medium-term periods.
Insider GOLD
ONLY R63pm

Moneyweb's premium subscription is a membership service which will give you access to a number of tools to take charge of your investments.
Or choose a yearly subscription at R630pa - SAVE R126

Get instant access to all our tools and content. Monthly subscription can be suspended at any time.

Podcasts

GO TO SHOP CART

Follow us:

Search Articles:Advanced Search
Click a Company:
server: 172.17.0.2